GlassScriptPhysician profile
Jenny Tran
NPI 1568889723
$777.06
in general payments reported to CMS, 2019-2025
11 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.10 · 2022: $216 · 2023: $268 · 2024: $46.53 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $461.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $334.35 | 2021-2025 | Relistor |
| Idorsia Pharmaceuticals US INC | $103.56 | 2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.48 | 2023 | |
| Abbvie INC. | $51.70 | 2021 | |
| Madrigal Pharmaceuticals | $42.24 | 2025 | Rezdiffra |
| Lilly USA, LLC | $37.48 | 2023 | Mounjaro |
| Exact Sciences Corporation | $31.58 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $28.14 | 2022 | |
| Novo Nordisk INC | $23.31 | 2024 | Rybelsus |
| Intercept Pharmaceuticals, INC. | $23.22 | 2024 | |
| Mayne Pharma Commercial LLC | $3.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.